How can works of art be the means for conveying the voice of patients at our R&D Institute in Paris-Saclay? Inspired by an original idea 💡 from the Servier Saclay Research & Development Patient Board, Art in Saclay exemplifies our desire to create strong ties between patients, R&D, and art. 👨🎨 The exhibition opened in June 2024. It bears witness to representations of patients’ voices, experiences and lives, at the very heart of our R&D Institute in Paris-Saclay and within range of researchers. These unprecedented encounters between artists and patients are on display for all to see through the original works that testify to their meeting, as are the works by talented patient-artists, direct expressions of the patient voice. Listen 🎥👇 to Marta Garcia, Chief Patient Officer R&D, share with us the genesis of this project and its challenges. Learn more about the Art in Saclay project 👉 https://swll.to/JUdK2 #patient #art #WeAreServier #MovedByYou
Servier
Fabrication de produits pharmaceutiques
Committed to therapeutic progress to serve patient needs
À propos
Fondé pour servir la santé, Servier est un groupe pharmaceutique international gouverné par une Fondation, qui aspire à avoir un impact sociétal significatif pour les patients et pour un monde durable. Son modèle unique de gouvernance lui permet de servir pleinement sa vocation avec une vision à long terme : être engagé pour le progrès thérapeutique au bénéfice des patients. Les 21 900 collaborateurs qui composent le Groupe sont engagés autour de cette vocation commune, source d’inspiration au quotidien. Leader mondial en cardiologie, Servier a pour ambition de devenir un acteur focalisé et innovant en oncologie en ciblant des cancers difficiles à traiter. C’est pourquoi le Groupe consacre plus de 70 % de son budget de R&D au développement de thérapies ciblées et innovantes en oncologie. Les neurosciences et les maladies immuno-inflammatoires constituent un futur relais de croissance. Dans ces domaines, Servier se focalise sur un nombre restreint de pathologies spécifiques dans lesquelles une caractérisation précise des patients permet de proposer une réponse thérapeutique ciblée, grâce à la médecine de précision. Pour favoriser l’accès à des soins de qualité pour tous, et à moindre coût, le Groupe propose également une offre de médicaments génériques couvrant la majorité des pathologies, en s’appuyant sur des marques fortes en France, en Europe de l’Est, au Brésil et au Nigeria. Dans tous ces domaines, le Groupe intègre la voix du patient à chaque étape du cycle de vie du médicament. Servier, dont le siège social est basé en France, s’appuie sur une solide implantation géographique dans plus de 150 pays et a réalisé, en 2023, un chiffre d’affaires de 5,3 milliards d’euros. --- Si vous avez constaté ou si vous pensez être sujet à un problème de santé lié à l’utilisation d’un médicament Servier ou de tout autre produit de santé Servier, rendez-vous sur servier.com
- Site web
-
https://servier.com
Lien externe pour Servier
- Secteur
- Fabrication de produits pharmaceutiques
- Taille de l’entreprise
- + de 10 000 employés
- Siège social
- Suresnes
- Type
- Société civile/Société commerciale/Autres types de sociétés
Lieux
-
Principal
50 rue Carnot
92150 Suresnes, FR
Employés chez Servier
Nouvelles
-
💬 For the first issue of Insights by Servier, we had the opportunity to interview Mathieu Lamiaux, Managing Director and Senior Partner at Boston Consulting Group (BCG), and Jerome Klein, Head of Corporate Strategy at Servier, about the opportunities and challenges of being a mid-size company in the pharmaceutical sector. 📣 Listen to Mathieu Lamiaux talk about the role of mid-size pharmaceutical companies and how that can bring its own rewards. Read the full interview with Mathieu Lamiaux and Jerome Klein on the opportunities and challenges for mid-size pharma in the latest issue of Insights by Servier 👉 https://lnkd.in/eNQwqyFC #WeAreServier #InsightsByServier #MidSizePharma
-
-
🎉 Congratulations to kyron.bio, winner of our Golden Ticket to Spartners by Servier & BioLabs France! kyron.bio is at the forefront of synthetic biology, developing advanced biomanufacturing processes for sustainable production. Their expertise lies in engineering microorganisms to produce high-value compounds, addressing global challenges in health, agriculture, and the environment with eco-friendly and cost-effective solutions. As a part of this year’s contest, kyron.bio will benefit from the latest research equipment, shared infrastructure, and numerous programs and services offered in Spartners by Servier & BioLabs. Learn more about Spartners by Servier & BioLabs France 👉 https://lnkd.in/eBa9FKzG #innovation #startup #biotech
-
Pharmaceutical companies can be divided into 3 major groups: ➡️ Biotech companies ➡️ Mid-size pharma companies ➡️ Big-pharma companies Read the full interview with Mathieu Lamiaux and Jerome Klein as they talk about the opportunities and challenges for mid-size pharma in the latest issue of Insights by Servier 👉 https://lnkd.in/eNQwqyFC #WeAreServier #InsightsByServier #PharmaceuticalIndustry
Ce contenu n’est pas disponible ici
Accédez à ce contenu et plus encore dans l’application LinkedIn
-
🔬 In the first issue of Insights by Servier, our digital magazine launched in March, we explore the unique advantages and challenges faced by mid-size pharmaceutical companies with Mathieu Lamiaux, Managing Director and Senior Partner at Boston Consulting Group (BCG), and Jerome Klein, Head of Corporate Strategy at Servier. 💡 Highlighting their ability to innovate by targeting smaller patient groups and less competitive markets, we look at how these companies leverage their independence and long-term vision to excel in the industry. ✅ One key opportunity is investing in underserved geographical areas where other players are not yet present. A significant challenge, however, is having to compete with the extensive R&D budgets available to big pharma. Follow this link to read the full interview 👉 https://lnkd.in/eNQwqyFC #WeAreServier #InsightsByServier #PharmaceuticalIndustry
-
Aitia is an American company specializing in the development and application of causal AI and Digital Twins in order to discover the next generation of therapies for patients. In May 2023, we signed a multi-year agreement with Aitia, with the aim of discovering and developing novel drug targets and drug candidates for pancreatic cancer. 💬 Listen to Colin Hill, CEO and Co-Founder of Aitia, talk about Digital Twins in the field of human health. #WeAreServier #InsightsByServier #DigitalTwins
-
-
👀🎬 A look back on the first edition of #THRPTX. Few days ago, we hosted the inaugural Therapeutics Innovation Summit (THRPTX) at our R&D Institute at Paris-Saclay. This groundbreaking event brought together world-renowned scientists, researchers, and industry leaders to explore the frontiers of medical innovation, with a focus on oncology. 🔎 From AI-driven drug discovery to cutting-edge immunotherapies, the discussions illuminated pathways to transform patient care. Prof. William G. Kaelin, 2019 Nobel Laureate in Medicine, set the tone with his inspiring keynote on cellular adaptation to oxygen availability. 👉 The summit exemplified our commitment to open innovation and collaborative research. By fostering dialogue between diverse stakeholders, we aim to accelerate therapeutic progress and address unmet medical needs. 🙏 We're immensely grateful to all participants for their invaluable contributions. The insights gained will fuel our ongoing efforts to develop innovative solutions for patients facing cancer. Read more 👉 https://swll.to/xDshrVA #WeAreServier #MovedByYou #innovation #health
-
#EVF is now over! It was great to share the latest vascular-health research and scientific innovations with our peers. Learn more about our commitments 👉 https://swll.to/0M3oKpy #EVFCongress #VenousDiseases #VascularHealth
-
-
-
-
-
+1
-
-
#ESMOGI2024 is now over! It was great to share the latest scientific and medical advances in gastrointestinal cancers with our peers. Learn more about Servier’s commitments 👉 https://swll.to/yShIY #GICancer #gastrointestinalcancers #oncology #gastroenterology #cancer ESMO - European Society for Medical Oncology
-
-
Servier a republié ceci
⭐ SHINEDocs annual event: SEEDPODS day 5th edition ⭐ Our community of young talented researchers (#SHINEDocs) just had their annual event to showcase their innovative projects to all Servier collaborators and our key partners: #SeedpodsDay was a resounding success, thanks to you, the SHINEDocs, and all the participants who made the day such an unforgettable experience. Special congratulations to the Seedpods 5th edition winners: - 🏆 Raphael R. Steimbach: 1st best flashtalk - 🏆 Julie Le Naour: 2nd best flashtalk - 🏆 Clara Ramón Lozano: 3rd best flashtalk - 🏆 Daniel Herrero Saboya: Public choice award for his Flashtalk - 🏆 Emilie Gentilini: best 10 minutes presentation - 🏆 Marius Halliez: best poster Your #innovative work and outstanding presentations have truly made a lasting impression. Thanks a million to the Seedpods committee for the tremendous work in organizing such an incredible event : Selena Bouffette, Amandine Pignarre, Alexandre KHUU, Rose KHOUBAI, Malina Xiao, Estefania Tumbaco Valarezo, Faouzi Zarrouki Thanks to all #SHINEDocs for your commitment, creativity and team spirit. Your active participation enriched the exchanges and discussions, making this event a source of inspiration and collaboration for all. We also want to sincerely thank: - our sponsors for their support: Christophe Thurieau, Claude Bertrand, Olivier Laureau - our keynote speakers for their inspiring presentations: Ivana Jakšić and Susan Chase and our COM partners: Marie Paule Thognard, Justine Sénéchal Let's stay connected to continue sharing our ideas and successes. 🚀 📸 Malina Xiao #SHINEDocs #SeedpodsDay #Innovation #RnD #Talent #WeareServier
-